BRIEF- GSK, MMV say Tafenoquine receives Breakthrough Therapy title from FDA

Fri Dec 20, 2013 10:49am EST

Dec 20 (Reuters) - GlaxoSmithKline Plc : * Joint press release: GSK and mmv announce FDA breakthrough therapy designation for Tafenoquine for plasmodium vivax malaria * Tafenoquine is not yet approved or licensed for use anywhere in the world * Plans are underway to start a phase III study in 2014 * For more news, please click here

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.